PT  - JOURNAL ARTICLE
AU  - Kostakoglu, Lale
AU  - Gallamini, Andrea
TI  - Interim <sup>18</sup>F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift?
AID  - 10.2967/jnumed.113.120451
DP  - 2013 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 1082--1093
VI  - 54
IP  - 7
4099  - http://jnm.snmjournals.org/content/54/7/1082.short
4100  - http://jnm.snmjournals.org/content/54/7/1082.full
SO  - J Nucl Med2013 Jul 01; 54
AB  - Hodgkin lymphoma (HL) is a curable disease with currently available chemotherapy regimens. Major late morbidities can potentially be avoided in most limited-stage HL patients if the treatment can be adapted to the patient’s early response profile. The therapy efficacy can also be increased early during therapy in nonresponding HL patients with the addition of involved-field radiation therapy or a switch to an escalated therapy protocol, particularly in advanced-stage or unfavorable-risk patients. 18F-FDG PET is a well-established surrogate for tumor chemosensitivity early during therapy. The ongoing PET-adaptive clinical trials are testing the hypothesis that a decision can reliably be made on escalating or deescalating therapy based on interim PET results. Discussed in this review is the integral role of interim 18F-FDG PET in HL, challenges, critical issues to improve its accuracy, and the observations from completed interim PET studies and ongoing PET-adaptive clinical trials.